Federal regulations
- Combined Notice of FilingsJuly 6, 2026
I need the description of this document to create an accurate summary. Please provide the input description along with the title so I can identify the most SMB-relevant facts (deadline, dollar amount, affected industry, or scope).
- Records Governing Off-the-Record Communications; Public NoticeJuly 6, 2026
FCC public notice clarifies records requirements for off-the-record communications with agency staff, affecting broadcasters and telecommunications firms subject to FCC jurisdiction.
- Carbon and Certain Alloy Steel Wire Rod from Mexico: Final Results of Antidumping Duty Administrative Review; 2023-2024July 6, 2026
U.S. Department of Commerce finds that Mexican carbon and alloy steel wire rod producers made sales below normal value during the October 1, 2023 through September 30, 2024 review period.
- Certain Corrosion-Resistant Steel Products From the People's Republic of China: Initiation of Circumvention Inquiry on the Antidumping and Countervailing Duty OrdersJuly 6, 2026
The U.S. Department of Commerce is investigating whether corrosion-resistant steel products from China completed in Thailand circumvent existing antidumping and countervailing duty orders.
- Expedited Investigational New Drug Pilot Program; Request for Information; CorrectionJuly 6, 2026
FDA corrects contact information for the Expedited Investigational New Drug Pilot Program docket, which solicits public input on shortening timelines from drug identification to first-in-human clinical trials.
- Combined Notice of Filings #1July 6, 2026
I need the description to create the summary. Please provide the description field for "Combined Notice of Filings #1."
- Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical DevicesJuly 6, 2026
The FDA seeks OMB clearance for information collection procedures related to premarket approval of medical devices under the Paperwork Reduction Act.
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or EffectivenessJuly 6, 2026
FDA determines that vasopressin 0.9% injection was not withdrawn for safety or effectiveness reasons, allowing approval of generic abbreviated new drug applications if other regulatory requirements are met.
- Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I; Request for InformationJuly 6, 2026
The Office of the Assistant Secretary for Health seeks public comments on a proposed threshold for scheduling 7-hydroxymitragynine under the Controlled Substances Act.
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug ApplicationsJuly 6, 2026
FDA withdraws approval of 34 new drug applications across multiple applicants whose manufacturers requested withdrawal due to discontinued marketing.
Track Federal regulations for your business
Tell Bizmoon what your business does and we'll cut the Federal Register down to what actually matters.
Every rule is broken into specific to-dos with calendar dates.
We tell you which parts of your business each rule actually touches.
No legal jargon. Read the impact in two sentences.
Email + dashboard pings the moment something changes.
Healthcare draws more federal rulemaking than any other sector
After healthcare come the capital-heavy sectors: trade, transportation, energy, and finance. If you operate in one of them, the volume of change is relentless.
Federal rulemaking
- Healthcare and life sciences
- Trade and commerce
- Transportation and aviation
- Energy and utilities
- Finance
- Natural resources
- Other